Co-morbidities in a Retrospective Cohort of Prostate Cancer Patients.
Co-morbidities
Prostate Cancer
Retrospective Cohort
Journal
Ethnicity & disease
ISSN: 1945-0826
Titre abrégé: Ethn Dis
Pays: United States
ID NLM: 9109034
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
10
4
2020
pubmed:
10
4
2020
medline:
2
2
2021
Statut:
epublish
Résumé
To characterize rates of co-morbidity among prostate cancer patients treated with radical prostatectomy and to examine the association between co-morbidity status and race, clinical factors, and health behaviors for cancer control. Retrospective cohort study among prostate cancer patients treated with radical prostatectomy. Academic medical center located in the southeastern region of the United States. Patients with at least one of five co-morbid conditions considered were categorized as having a co-morbidity, and those without any were categorized as not having a co-morbid condition. Co-morbid conditions considered were hypertension, diabetes, heart problems, stroke, and high cholesterol, which had been recorded in the electronic medical record as part of their past medical history. Fifty-one percent of participants had a co-morbidity, with hypertension being the most common. The average number of co-morbidities among study participants was .87. In a multivariate logistic regression analysis, being diagnosed with prostate cancer within the past four years was associated with an increased likelihood of having a co-morbidity (OR=4.71, 95% CI=2.69, 8.25, P=.0001) compared with diagnosis five or more years ago. Age was also associated with an increased likelihood of having a co-morbidity (OR=1.30, 95% CI=1.005, 1.68, P=.05). In this study cohort, race, stage at diagnosis, and PSA level were not statistically associated with co-morbidity status. Better chronic disease management is needed among prostate cancer survivors through more effective survivorship care planning and interventions that promote health behaviors.
Identifiants
pubmed: 32269460
doi: 10.18865/ed.30.S1.185
pii: ed.30.S1.185
pmc: PMC7138439
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-192Subventions
Organisme : NCI NIH HHS
ID : P30 CA138313
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK123704
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD010706
Pays : United States
Informations de copyright
Copyright © 2020, Ethnicity & Disease, Inc.
Déclaration de conflit d'intérêts
Competing Interests: None declared.
Références
CA Cancer J Clin. 2012 Jul-Aug;62(4):243-74
pubmed: 22539238
Prostate Cancer Prostatic Dis. 2013 Mar;16(1):62-6
pubmed: 22907512
J Clin Oncol. 2011 Apr 1;29(10):1335-41
pubmed: 21357791
Natl Vital Stat Rep. 2018 Jul;67(6):1-77
pubmed: 30248017
Health Educ Res. 2017 Jun 1;32(3):207-218
pubmed: 28335038
J Cancer Surviv. 2015 Dec;9(4):641-9
pubmed: 25716644
Prev Med. 2017 Dec;105:169-175
pubmed: 28917949
JAMA Oncol. 2017 Aug 1;3(8):1035-1042
pubmed: 28208186
Inform Prim Care. 2006;14(3):167-73
pubmed: 17288702
Prev Chronic Dis. 2017 Oct 19;14:E101
pubmed: 29049018
CA Cancer J Clin. 2014 Jul-Aug;64(4):225-49
pubmed: 24916760
J Cancer Educ. 2016 Mar;31(1):63-9
pubmed: 25524391
Cancer. 2014 May 1;120(9):1290-314
pubmed: 24343171
JMIR Res Protoc. 2018 Feb 26;7(2):e51
pubmed: 29483070
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Semin Radiat Oncol. 2012 Oct;22(4):284-94
pubmed: 22985811
J Clin Epidemiol. 2000 Dec;53(12):1258-67
pubmed: 11146273
J Oncol Pract. 2016 Aug;12(8):e800-9
pubmed: 27407167
NCHS Data Brief. 2017 Oct;(289):1-8
pubmed: 29155682
Ann Intern Med. 2013 May 21;158(10):709-17
pubmed: 23689764
Prostate Cancer. 2011;2011:245642
pubmed: 22096652
J Urol. 2007 Jun;177(6):2106-31
pubmed: 17509297